Ibandronate sodium monohydrate是一种口服有效的法尼基焦磷酸合酶抑制剂，通过阻断甲羟戊酸途径，抑制RAS、RHO等小GTP酶的异戊二烯化修饰，进而诱导肿瘤细胞凋亡并抑制骨吸收作用。该化合物能够抑制ER+乳腺癌细胞增殖，促进促凋亡基因FAS表达，并与抗雌激素药物产生协同抗肿瘤效应，目前主要用于骨质疏松症及骨转移性肿瘤(如乳腺癌骨转移)的相关研究。
| 英文别名 (English Synonym) | Ibandronate sodium monohydrate |
| 中文名称 (Chinese Name) | 伊班膦酸钠一水合物；伊班膦酸钠单水合物 |
| 靶点 (Target) | Others |
| 通路 (Pathway) | Others |
| CAS号 (CAS NO.) | 138926-19-9 |
| 分子式 (Formula) | C9H24NNaO8P2 |
| 分子量 (Molecular Weight) | 359.23 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于H2O |
-25~-15℃保存，有效期3年
[1] Journe F, Chaboteaux C, Magne N, Duvillier H, Laurent G, Body JJ. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8(1):R2. doi: 10.1186/bcr1363. Epub 2005 Dec 12. PMID: 16417650; PMCID: PMC1413981.
[2] Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002 Oct;29(10):2200-8. PMID: 12375334.
